Go Back To Menu
Close
- Mailing Form
-
Medical Report*
-
Go Back To Menu
Vaginal cancer refers to malignant tumors originating from the vaginal mucosa, a relatively rare type of female reproductive system cancer, most common in women over the age of 50. Its occurrence is related to persistent HPV infection, a history of cervical cancer treatment, and immune deficiency.
Most vaginal cancers are squamous cell carcinomas, but melanoma, sarcoma, adenocarcinoma, and other histological types also exist. Although primary vaginal cancer is rare, metastatic vaginal cancers or local spread from adjacent female reproductive organ malignancies are not uncommon. Thus, most vaginal malignancies are metastatic, commonly originating from endometrial cancer, cervical cancer, vulvar cancer, ovarian cancer, breast cancer, rectal cancer, and kidney cancer. Spread may occur directly (as in cervical cancer, vulvar cancer, or endometrial cancer) or via lymphatic or hematogenous dissemination (as in breast cancer, ovarian cancer, or kidney cancer).
Vaginal cancer usually develops slowly, with atypical early symptoms, often leading to diagnosis at an advanced stage. With the advancement of immunotherapy and minimally invasive technology, treatment methods for this disease are becoming increasingly diverse.
Vaginal cancer is a low-incidence tumor worldwide, accounting for about 1%–2% of female reproductive tract cancers. In countries such as Europe, the U.S., Japan, and South Korea, where cervical cancer prevention and control systems are well-established, the incidence of vaginal cancer remains relatively stable. However, in Southeast Asia and Africa, where HPV screening rates are low, the occurrence of vaginal cancer cannot be ignored.
Squamous cell carcinoma is the most common histological type of vaginal cancer, with the average age at diagnosis around 60 years, though cases in women in their 20s and 30s also occur. The incidence of squamous cell carcinoma increases with age.
1. Local spread endangering surrounding organs
If not detected early, vaginal cancer spreads from the mucosal layer to surrounding tissues, involving organs such as the bladder and rectum, causing urination and defecation abnormalities, increasing surgical risk, and reducing quality of life.
2. Metastatic risk affecting survival rate
Some vaginal cancers metastasize via lymph nodes to the pelvis and distant organs, especially the lungs and liver. Such metastasis causes systemic symptoms, seriously impacting survival time and treatment efficacy.
3. High recurrence rate requiring long-term follow-up
Even after initial treatment, the risk of recurrence remains significant, often occurring in local or pelvic areas. Therefore, long-term follow-up and regular imaging examinations are essential to prevent recurrence.
4. Dual physical and psychological burden
The occurrence of vaginal cancer and its treatments (such as surgery or radiotherapy) may affect sexual life, excretory function, and women’s mental health, leading to long-term anxiety and identity crises, requiring multidimensional rehabilitation interventions.
Immune reconstruction cell therapy extracts the patient’s own immune cells and rebuilds their ability to recognize and attack tumors. This therapy offers advantages in synergistic anti-cancer effects, enhancing physical strength, and delaying recurrence. It is suitable for postoperative consolidation or late-stage control, with safe and controllable efficacy, and is gradually being integrated into comprehensive treatment systems.
Immune reconstruction cell therapy extracts the patient’s own immune cells and rebuilds their ability to recognize and attack tumors. This therapy offers advantages in synergistic anti-cancer effects, enhancing physical strength, and delaying recurrence. It is suitable for postoperative consolidation or late-stage control, with safe and controllable efficacy, and is gradually being integrated into comprehensive treatment systems.
During actual treatment, patients undergoing traditional methods such as surgery, radiotherapy, and chemotherapy often face immune dysfunction, increased infection risks, and slow recovery. To help patients better sustain treatment, improve tolerance, and enhance quality of life, phased immune reconstruction plans tailored to different treatment cycles should be scientifically developed.
● Short-term plan: Rapidly enhance immunity through immune cell reinfusion to improve the effectiveness of anti-cancer treatment.
● Mid-term plan: Reduce the side effects of traditional treatments, promote physical recovery, and complete standardized treatment courses.
● Long-term plan: Enhance overall immunity through immune cell reconstruction, gut immune reconstruction, elemental immune reconstruction, and immune nutrition reconstruction, thereby improving quality of life and prolonging survival.
1. Surgical resection
Early vaginal cancer can be treated with local resection or wide vaginectomy. For localized tumors without metastasis, outcomes are favorable, but protection of structures such as the urethra and bladder must be considered, making surgery relatively difficult.
2. Radiotherapy
As one of the main treatments, radiotherapy is suitable for all stages of vaginal cancer, particularly for patients unable to undergo surgery or requiring postoperative adjuvant therapy. Modern precision radiotherapy can focus on the tumor area, minimizing damage to normal tissues and improving local control rates.
3. Chemotherapy
Chemotherapy is generally used as an adjuvant method for postoperative recurrence prevention or combined with radiotherapy. Platinum-based drugs are the preferred agents. Chemotherapy also shows some efficacy in metastatic or recurrent cases, but side effects can be significant.
4. Minimally invasive approaches
With the advancement of endoscopic and electrosurgical technologies, some early vaginal cancers can be removed via minimally invasive transvaginal surgery. This method causes less trauma and faster recovery, suitable for early patients without significant spread, and is increasingly favored.
Although vaginal cancer is a rare disease, its harms should not be underestimated, particularly in advanced cases where survival quality and lifespan are affected. Experts at United Life International Medical Center point out that early screening, active treatment, combined with immune cell therapy and minimally invasive surgery, will bring more recovery possibilities for patients.
